CY1108292T1 - Αντικαρκινικο σκευασμα που περιεχει dmxaa - Google Patents
Αντικαρκινικο σκευασμα που περιεχει dmxaaInfo
- Publication number
- CY1108292T1 CY1108292T1 CY20081100909T CY081100909T CY1108292T1 CY 1108292 T1 CY1108292 T1 CY 1108292T1 CY 20081100909 T CY20081100909 T CY 20081100909T CY 081100909 T CY081100909 T CY 081100909T CY 1108292 T1 CY1108292 T1 CY 1108292T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dmxaa
- cancer
- compounds
- container
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Portable Nailing Machines And Staplers (AREA)
- Control Of Eletrric Generators (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με τη χρήση ενώσεων όπως ενώσεων της τάξης του ξανθενονοξεικού οξέος όπως 5,6-διμεθυλοξανθενον-4-οξεικό οξύ (DMXAA) για τη θεραπεία του καρκίνου, όπου οι ενώσεις χορηγούνται γαστρεντερικώς, κατά προτίμηση από το στόμα. Ειδικότερα, η εφεύρεση ασχολείται με τη χρήση τέτοιων ενώσεων, όπου η ένωση μεταφέρεται στη θέση δράσης στον ασθενή που πρόκειται να δεχθεί τη θεραπεία σε δύο ή περισσότερες δόσεις.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0225508A GB2394658A (en) | 2002-11-01 | 2002-11-01 | Oral anti-cancer composition |
EP03773835A EP1572194B1 (en) | 2002-11-01 | 2003-10-30 | Anti-cancer composition comprising dmxaa |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108292T1 true CY1108292T1 (el) | 2014-02-12 |
Family
ID=9947036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100909T CY1108292T1 (el) | 2002-11-01 | 2008-08-25 | Αντικαρκινικο σκευασμα που περιεχει dmxaa |
Country Status (13)
Country | Link |
---|---|
US (1) | US7585893B2 (el) |
EP (1) | EP1572194B1 (el) |
JP (1) | JP2006508091A (el) |
AT (1) | ATE401882T1 (el) |
AU (1) | AU2003282215A1 (el) |
CY (1) | CY1108292T1 (el) |
DE (1) | DE60322425D1 (el) |
DK (1) | DK1572194T3 (el) |
ES (1) | ES2311740T3 (el) |
GB (1) | GB2394658A (el) |
PT (1) | PT1572194E (el) |
SI (1) | SI1572194T1 (el) |
WO (1) | WO2004039363A1 (el) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60027719T2 (de) * | 1999-06-14 | 2007-04-26 | Cancer Research Technology Ltd. | Krebstherapie |
EP1311262A4 (en) | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | COMBINED TREATMENT AGAINST CANCER |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
SI3332789T1 (sl) * | 2004-12-22 | 2022-08-31 | Merck Serono Sa, Centre Industriel | Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze |
JP2009506019A (ja) * | 2005-08-26 | 2009-02-12 | アンティソーマ・ピーエルシー | 癌治療のための組み合わせ |
WO2007087113A2 (en) | 2005-12-28 | 2007-08-02 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
EA020805B1 (ru) | 2006-05-24 | 2015-01-30 | Мерк Сероно С.А. | Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза |
WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
CA2739464C (en) | 2008-10-03 | 2020-03-31 | Opko Curna, Llc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
WO2010045551A1 (en) * | 2008-10-17 | 2010-04-22 | Concert Pharmaceuticals, Inc. | Xanthenone-4-acetic acid derivatives |
CN102317458B (zh) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
RU2618688C2 (ru) | 2008-12-04 | 2017-05-10 | КьюРНА,Инк.,US | Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена |
MX2011005912A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular. |
ES2560107T3 (es) | 2009-02-12 | 2016-02-17 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF |
EP2408919B1 (en) | 2009-03-16 | 2017-10-18 | CuRNA, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
ES2627763T3 (es) | 2009-03-17 | 2017-07-31 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1 |
KR101835889B1 (ko) | 2009-05-06 | 2018-03-08 | 큐알엔에이, 인크. | 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료 |
JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療 |
CN102459597B (zh) | 2009-05-08 | 2020-06-30 | 库尔纳公司 | 通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病 |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
CN102549158B (zh) | 2009-05-22 | 2017-09-26 | 库尔纳公司 | 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病 |
US8791085B2 (en) | 2009-05-28 | 2014-07-29 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
WO2010148065A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CN102597238B (zh) | 2009-06-24 | 2016-06-29 | 库尔纳公司 | 通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病 |
CN102482672B (zh) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 |
JP2013500017A (ja) | 2009-07-24 | 2013-01-07 | カッパーアールエヌエー,インコーポレイテッド | サ−チュイン(sirt)への天然アンチセンス転写物の阻止によるサ−チュイン(sirt)関連疾患の治療 |
JP6128848B2 (ja) | 2009-08-05 | 2017-05-17 | クルナ・インコーポレーテッド | インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療 |
CN104313027B (zh) | 2009-08-11 | 2018-11-20 | 库尔纳公司 | 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病 |
KR101805213B1 (ko) | 2009-08-21 | 2017-12-06 | 큐알엔에이, 인크. | Chip에 대한 천연 안티센스 전사체의 억제에 의한 “hsp70-상호작용 단백질(chip)의 c-말단” 관련된 질환의 치료 |
EP2470657B1 (en) | 2009-08-25 | 2019-10-23 | CuRNA, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
CA2775111C (en) | 2009-09-25 | 2019-12-31 | Opko Curna, Llc | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
US9173895B2 (en) | 2009-12-16 | 2015-11-03 | Curna, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 |
NO2516648T3 (el) | 2009-12-23 | 2018-04-07 | ||
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
CA2785177C (en) | 2009-12-29 | 2019-09-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
KR101838305B1 (ko) | 2009-12-29 | 2018-03-13 | 큐알엔에이, 인크. | NRF1(Nuclear Respiratory Factor 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료 |
CN102791862B (zh) | 2009-12-31 | 2017-04-05 | 库尔纳公司 | 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病 |
KR101878501B1 (ko) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | 인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료 |
RU2612161C2 (ru) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы |
NO2524039T3 (el) | 2010-01-11 | 2018-04-28 | ||
CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
US8962586B2 (en) | 2010-02-22 | 2015-02-24 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1 |
WO2011123745A2 (en) | 2010-04-02 | 2011-10-06 | Opko Curna Llc | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
US9044494B2 (en) | 2010-04-09 | 2015-06-02 | Curna, Inc. | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 |
US9089588B2 (en) | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
CN102971423B (zh) | 2010-05-26 | 2018-01-26 | 库尔纳公司 | 通过抑制蛋氨酸硫氧化物还原酶a(msra)的天然反义转录物而治疗msra相关疾病 |
DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー,インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療 |
US8980860B2 (en) | 2010-07-14 | 2015-03-17 | Curna, Inc. | Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG |
ES2640755T3 (es) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4 |
EP2630241B1 (en) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
RU2608493C2 (ru) | 2010-11-23 | 2017-01-18 | Курна, Инк. | Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog |
EP2718439B1 (en) | 2011-06-09 | 2017-08-09 | CuRNA, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
BR112014005234A2 (pt) | 2011-09-06 | 2017-04-11 | Curna Inc | tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas |
ES2694592T3 (es) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
EP4241790A1 (en) | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Expression system for the treatment of cancer |
EP4241791A1 (en) | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Combined gene and radio therapy for the treatment of cancer |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2015265A1 (de) | 1969-03-29 | 1970-10-08 | Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) | Arylalkansäuren und Verfahren zu deren Herstellung |
US3655470A (en) * | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
FR2516922A1 (fr) * | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
DE3587500T2 (de) * | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
EP0278176B1 (en) * | 1986-12-23 | 1994-03-09 | Warner-Lambert Company | Compounds having antitumour and antibacterial properties |
US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
JPH01193227A (ja) | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
US5075287A (en) | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
AU6501390A (en) | 1989-09-21 | 1991-04-18 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
US5250296A (en) | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
EP0551200A1 (en) | 1992-01-07 | 1993-07-14 | National University Of Singapore | Protein phosphatase inhibitors for use in therapy |
CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
GB9308166D0 (en) | 1993-04-20 | 1993-06-02 | Cancer Res Campaign Tech | Cancer therapy |
GB9320484D0 (en) | 1993-10-05 | 1993-11-24 | Wellcome Found | Pharmaceutical combinations |
US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
AU5688596A (en) | 1995-04-13 | 1996-10-30 | Deutsche Om Arzneimittel Gmbh | Anti-cd14 antibodies for use in the induction of il-10 secre tion |
WO1996036347A1 (en) | 1995-05-17 | 1996-11-21 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
JPH0940690A (ja) | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
AU6714396A (en) | 1995-07-28 | 1997-02-26 | Trustees Of Boston University | Methods and compositions for treating cell proliferative disorders |
US5977077A (en) | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
WO1998025600A1 (en) | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Leukotriene antagonists for treatment or inhibition of gout |
UA47505C2 (uk) | 1996-12-13 | 2002-07-15 | Елі Ліллі Енд Компані | Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну |
EP0961617A4 (en) * | 1996-12-13 | 2002-08-07 | Lilly Co Eli | LEUKOTRINE ANTAGONISTS FOR TREATING FOCAL BRAIN CHEMISTRY |
WO1998042335A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating gout |
WO1998042650A2 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating cystic fibrosis |
AU6572298A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
US5914340A (en) | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
WO1998042345A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating cerebral focal stroke |
US5998454A (en) | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
HUP9904672A2 (hu) | 1997-03-21 | 2000-05-28 | Eli Lilly And Co. | Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták |
WO1998042336A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating gingivitis |
DE19721211A1 (de) | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren |
IL141627A0 (en) | 1998-08-24 | 2002-03-10 | Maxim Pharm Inc | Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents |
AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
PT1033364E (pt) * | 1999-03-01 | 2005-07-29 | Pfizer Prod Inc | Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide |
DE60027719T2 (de) * | 1999-06-14 | 2007-04-26 | Cancer Research Technology Ltd. | Krebstherapie |
US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
AU1916501A (en) | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
JP2003513914A (ja) | 1999-11-11 | 2003-04-15 | イーライ・リリー・アンド・カンパニー | 癌の処置のための腫瘍崩壊薬の組み合わせ |
WO2001034198A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
NZ517667A (en) | 1999-11-11 | 2004-05-28 | Lilly Co Eli | Oncolytic combinations for the treatment of cancer |
EP1259237A4 (en) * | 2000-02-17 | 2004-07-28 | Merck & Co Inc | TREATMENT OR PREVENTION OF PROSTATE CANCER USING A SELECTIVE COX-2 INHIBITOR MEDICINE |
JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
EP1311262A4 (en) * | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | COMBINED TREATMENT AGAINST CANCER |
GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
GB0321999D0 (en) | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
GB0517387D0 (en) | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
JP2009506019A (ja) | 2005-08-26 | 2009-02-12 | アンティソーマ・ピーエルシー | 癌治療のための組み合わせ |
-
2002
- 2002-11-01 GB GB0225508A patent/GB2394658A/en not_active Withdrawn
-
2003
- 2003-10-30 AT AT03773835T patent/ATE401882T1/de active
- 2003-10-30 EP EP03773835A patent/EP1572194B1/en not_active Expired - Lifetime
- 2003-10-30 JP JP2004547801A patent/JP2006508091A/ja active Pending
- 2003-10-30 DE DE60322425T patent/DE60322425D1/de not_active Expired - Lifetime
- 2003-10-30 ES ES03773835T patent/ES2311740T3/es not_active Expired - Lifetime
- 2003-10-30 DK DK03773835T patent/DK1572194T3/da active
- 2003-10-30 WO PCT/GB2003/004688 patent/WO2004039363A1/en active IP Right Grant
- 2003-10-30 PT PT03773835T patent/PT1572194E/pt unknown
- 2003-10-30 SI SI200331387T patent/SI1572194T1/sl unknown
- 2003-10-30 AU AU2003282215A patent/AU2003282215A1/en not_active Abandoned
-
2005
- 2005-04-28 US US11/116,798 patent/US7585893B2/en not_active Expired - Fee Related
-
2008
- 2008-08-25 CY CY20081100909T patent/CY1108292T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1572194E (pt) | 2008-11-03 |
EP1572194B1 (en) | 2008-07-23 |
GB2394658A (en) | 2004-05-05 |
US7585893B2 (en) | 2009-09-08 |
GB0225508D0 (en) | 2002-12-11 |
US20060009505A1 (en) | 2006-01-12 |
DK1572194T3 (da) | 2008-08-25 |
ATE401882T1 (de) | 2008-08-15 |
DE60322425D1 (de) | 2008-09-04 |
EP1572194A1 (en) | 2005-09-14 |
SI1572194T1 (sl) | 2008-12-31 |
WO2004039363A1 (en) | 2004-05-13 |
JP2006508091A (ja) | 2006-03-09 |
AU2003282215A1 (en) | 2004-05-25 |
ES2311740T3 (es) | 2009-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108292T1 (el) | Αντικαρκινικο σκευασμα που περιεχει dmxaa | |
CY1105617T1 (el) | Νεα αρωματικα παραγωγα των φθορογλυκοσιδων, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
CY1106283T1 (el) | Κινολινυλ-πυρρολοπυραζολες | |
PE20041000A1 (es) | Pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina | |
EA200600317A1 (ru) | Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты) | |
CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
CY1116494T1 (el) | Θεραπευτικη αγωγη θρομβοεμβολικων διαταραχων με ριβαροξαβανη | |
EA200400971A1 (ru) | Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения | |
CY1105915T1 (el) | Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar | |
EA200601239A1 (ru) | Замещённые хинолиновые соединения | |
CY1109104T1 (el) | 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου | |
CY1110177T1 (el) | Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης | |
DE60313624D1 (de) | Derivate von heteroarylnitrilverbindungen | |
EA200700321A1 (ru) | Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы | |
PE20040999A1 (es) | Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas | |
CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
CY1110986T1 (el) | Αζολια ως αναστολεις της αποκαρβοξυλασης μηλονυλο-συνενζυμου α χρησιμα ως μεταβολικοι διαμορφωτες | |
CY1105387T1 (el) | Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
NO20065079L (no) | Materialer og metoder for behandling av koaguleringssykdommer | |
DK1594885T3 (da) | Lægemiddel til vækstinhibering af tumorer | |
ATE417856T1 (de) | Motilidverbindungen | |
CY1112012T1 (el) | Αμινουχα παραγωγα β-ομοανδροστανων και β-ετεροανδροστανων |